US PDUFA V deal adds 60-day cushion for new drug, biologic reviews
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and the biopharmaceutical industry have agreed to extend by two months the deadline by which the FDA must complete its review of marketing applications for new molecular entities and innovator biologics1.